On July 30, 2019 Peptomyc reported that amounting to 2.2 million euros over 2 years, this latest funding from the EU Horizon 2020 Research and Innovation programme is a huge step toward clinical trials, due to start in 2020 (Press release, Peptomyc, JUL 30, 2019, View Source [SID1234555337]). The grant will help with regulatory safety studies and activities of Peptomyc’s first product, OMO-103, including its clinical batch production, and the design, recruitment of patients and performance of Phase I/IIa clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Peptomyc and the laboratory of Dr. Soucek previously received an ERC Consolidator Grant and 2 separate Proof-of-Concept grants from the Horizon 2020 programme, and also an SME Instrument Phase I. These have all contributed significantly to bringing OMO-103 to its current level of development.